PMID- 22922126
OWN - NLM
STAT- MEDLINE
DCOM- 20130305
LR  - 20161125
IS  - 1872-8332 (Electronic)
IS  - 0169-5002 (Linking)
VI  - 78
IP  - 2
DP  - 2012 Nov
TI  - Quantitative modifications of TNM staging, clinical staging and therapeutic 
      intent by FDG-PET/CT in patients with non small cell lung cancer scheduled for 
      radiotherapy--a retrospective study.
PG  - 148-52
LID - S0169-5002(12)00437-0 [pii]
LID - 10.1016/j.lungcan.2012.08.001 [doi]
AB  - It is obvious that FDG-PET has added value to CT, but there is still insufficient 
      data to define the role of FDG-PET/CT in clinical practice. Usually data are 
      gathered from multiple sources and in consequence the information obtained is 
      heterogeneous and not always comparable between patients. To alleviate this lack 
      of data, we attempted to investigate the differences in staging and therapeutic 
      intent as compared with conventional staging in non small cell lung cancer 
      (NSCLC) patients scheduled for RT after adding FDG-PET/CT to conventional staging 
      in 104 included subjects. In contrary to the multicentric studies relying on 
      patients medical records from outside institutions, these data were generated 
      entirely with the institution's PET/CT unit. Significant modifications of both, 
      M-stage and clinical stage were detected after inclusion of FDG-PET/CT data 
      (p<0.001), while there was no statistically significant T- and N-stage 
      modification. Overall implenting FDG-PET/CT revised RT intention decision in 34% 
      of patients. FDG-PET/CT provides enhanced staging capabilities compared to 
      conventional CT in staging of non small cell lung carcinoma and allows improved 
      selection of patients suitable for curative intention, while avoiding unnecessary 
      irradiation and costs in patients eligible to palliative intention.
CI  - Copyright (c) 2012 Elsevier Ireland Ltd. All rights reserved.
FAU - Abramyuk, Andrij
AU  - Abramyuk A
AD  - OncoRay--National Center for Radiation Research in Oncology, Biological and 
      Molecular Imaging, Medical Faculty and University Hospital Carl Gustav Carus, TU 
      Dresden, Germany. anabr@gmx.de
FAU - Appold, Steffen
AU  - Appold S
FAU - Zophel, Klaus
AU  - Zophel K
FAU - Hietschold, Volker
AU  - Hietschold V
FAU - Baumann, Michael
AU  - Baumann M
FAU - Abolmaali, Nasreddin
AU  - Abolmaali N
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20120822
PL  - Ireland
TA  - Lung Cancer
JT  - Lung cancer (Amsterdam, Netherlands)
JID - 8800805
RN  - 0 (Radiopharmaceuticals)
RN  - 0Z5B2CJX4D (Fluorodeoxyglucose F18)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Carcinoma, Non-Small-Cell Lung/*diagnostic imaging/pathology/*radiotherapy
MH  - Diagnostic Errors
MH  - Female
MH  - Fluorodeoxyglucose F18
MH  - Humans
MH  - Lung Neoplasms/*diagnostic imaging/pathology/*radiotherapy
MH  - Male
MH  - Middle Aged
MH  - Multimodal Imaging
MH  - Neoplasm Staging
MH  - Positron-Emission Tomography
MH  - Radiopharmaceuticals
MH  - Radiotherapy Planning, Computer-Assisted
MH  - Retrospective Studies
MH  - Tomography, X-Ray Computed
EDAT- 2012/08/28 06:00
MHDA- 2013/03/06 06:00
CRDT- 2012/08/28 06:00
PHST- 2012/05/15 00:00 [received]
PHST- 2012/06/19 00:00 [revised]
PHST- 2012/08/02 00:00 [accepted]
PHST- 2012/08/28 06:00 [entrez]
PHST- 2012/08/28 06:00 [pubmed]
PHST- 2013/03/06 06:00 [medline]
AID - S0169-5002(12)00437-0 [pii]
AID - 10.1016/j.lungcan.2012.08.001 [doi]
PST - ppublish
SO  - Lung Cancer. 2012 Nov;78(2):148-52. doi: 10.1016/j.lungcan.2012.08.001. Epub 2012 
      Aug 22.